Q2 2026 Drug Updates: New FDA Approvals, Generics and Biosimilars to Watch 

By Long Tran, Pharm D; Beckie Fenrick, Pharm D; and Jason Peterson, RPh   

In Q2 2026, the FDA approved several notable therapies in high-impact areas including obesity, diabetes, HIV, psoriasis and hypertension. These approvals reflect continued innovation in oral treatments, longer dosing intervals and new mechanisms of action. At the same time, growing generic and biosimilar competition is creating new affordability opportunities across several categories. 

Together, these developments represent meaningful clinical progress and may influence pharmacy benefit strategy, formulary decisions, utilization management and cost planning for employers, TPAs and plan sponsors. 

New FDA Approvals to Watch in Q2 2026 

Icotyde (icotrokinra) 

Icotyde was approved in March 2026 for adults and pediatric patients age 12 and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. 

• Utilization Management: Prior authorization and quantity limits can help confirm diagnosis, disease severity, labeled use and appropriate dosing. 
• Cost Impact: Annual WAC is $100,801, or about $8,285 per 30 days, competing with oral Sotyktu ($86,816 Annual WAC) and injectable biologics such as Skyrizi, (~$103,299 Annual WAC). 
• Clinical Considerations: Icotyde is a first-in-class oral IL-23 therapy, the same pathway used by leading biologics such as Skyrizi and Tremfya, and outperformed oral Sotyktu in head-to-head trials, though its cost may warrant careful formulary review. 

Awiqli (insulin icodec)  

Awiqli was approved in March 2026 as the first once-weekly insulin for improving glycemic control in adults with type 2 diabetes, used in addition to diet and exercise. The approval does not include type 1 diabetes, narrowing initial use to adults with type 2 diabetes who may benefit from less frequent basal insulin dosing. 

• Utilization Management: Prior authorization and quantity limits may help confirm use aligns with the labeled adult type 2 diabetes indication. 
• Cost Impact: WAC is pending at launch. 
• Clinical Considerations: Awiqli may benefit patients who have difficulty adhering to daily injections or frequent dose adjustments, with U.S. launch expected in the second half of 2026. 

Foundayo (orforglipron) 

Foundayo was approved in April 2026 as an oral treatment for adults with obesity or for adults who are overweight and have at least one weight-related comorbidity, to be used with a reduced-calorie diet and increased physical activity. 

• Utilization Management: Prior authorization and quantity limits can help confirm labeled use, including obesity or overweight status with a qualifying comorbidity, and use alongside diet and exercise. 
• Cost Impact: WAC is $649 per 30 days, about half the monthly WAC of oral Wegovy at $1,349 per 30 days. 
• Clinical Considerations: Foundayo adds another oral GLP-1 option for weight management and may be easier to use than oral Wegovy because it does not require fasting, limited water intake or a 30-minute wait after dosing. 

Idvynso (doravirine/islatravir) 

Idvynso was approved in April 2026 for adults with HIV-1 who are virologically suppressed, have no history of virologic failure, and have no known HIV mutations expected to reduce response to doravirine. 

• Utilization Management: Prior authorization and quantity limits may be considered to align use with Idvynso’s narrower maintenance-only indication, though HIV treatment is highly individualized, and most regimens are not heavily managed. 
• Cost Impact: WAC is $4,455 per 30 days, which is generally in line with leading HIV single-tablet regimens such as Biktarvy at $4,216 per 30 days and Dovato at $3,250 per 30 days. 
• Clinical Considerations: Idvynso is a complete, once-daily single-tablet regimen for adults with virologically suppressed HIV-1, but its role is narrower than established options such as Biktarvy and Dovato because it is not indicated for treatment-naïve patients. 

Baxfendy (baxdrostat) 

Baxfendy was approved in May 2026 for use with other antihypertensive medications to lower blood pressure in adults whose hypertension is not adequately controlled. 

• Utilization Management: Prior authorization and quantity limits may help target use to adults with persistently uncontrolled hypertension despite standard therapy. 
• Cost Impact: WAC is $900 per 30 days, higher than Tryvio at $775 per 30 days and substantially above generic fourth-line therapies such as spironolactone and eplerenone. 
• Clinical Considerations: Baxfendy is a first-in-class oral aldosterone synthase inhibitor that may offer a new add-on option for uncontrolled hypertension and compete with guideline-recommended fourth-line or later treatments, including generics and Tryvio. 

Select Generic Launches 

Generic launches continued across several categories in Q2 2026. The level of expected competition varies by product, which may affect the degree of pricing pressure and future savings opportunity. 

* WAC price varies by strength; ** AG = authorized generic 

Biosimilar Approvals Continue 

Several biosimilars were approved during the quarter, continuing the expansion of competition across categories that may affect both pharmacy and medical benefit strategy: 

•  In March 2026, Ponlimsi (denosumab-adet), a biosimilar to Prolia, was approved for all reference product indications, entering a denosumab biosimilar market that already includes seven competitors. 
• In May 2026, Langlara (insulin glargine-aldy), a biosimilar to Lantus, was approved for adults and pediatric patients with type 1 diabetes and for adults with type 2 diabetes, joining insulin glargine biosimilars such as Semglee and Rezvoglar. 
• In May 2026, Immgolis (golimumab-sldi) and Immgolis Intri (golimumab-sldi) became the first biosimilars approved for Simponi and Simponi Aria, respectively, although launch timing remains uncertain because of ongoing litigation. 

What Q2 2026 FDA Drug Updates Mean for Plan Sponsors 

Q2 2026 drug approvals and generic entries reflect several important market themes: oral alternatives to injectable therapies, extended dosing options, novel mechanisms of action, more affordable treatment options and continued biosimilar expansion. 

For employers, TPAs and plan sponsors, these developments may create new opportunities for clinical flexibility and cost management. They also reinforce the need for disciplined formulary strategy, appropriate utilization management, and close monitoring of launch timing, pricing and competitive positioning. 

The organizations that stay closest to these changes will be better positioned to make informed pharmacy benefit decisions and manage trend over time. 

If you’re evaluating how these developments may shape your pharmacy benefit strategy, reach out to Navion to continue the conversation.